Capricor Therapeutics(DE:4LN2)
€8.95+0.78 (+9.58%)
DE:4LN2
Capricor Therapeutics hedge funds
€8.95
At close:+0.78 (+9.58%)
Capricor Therapeutics (4LN2) Hedge Fund Trading Activity
0 Followers
Trend: ▼ Hedge Funds Decreased Holdings by 149.4K Shares Last Quarter
Hedge Fund Holdings in 4LN2
Based on the 13F filings of 489 Hedge Funds tracked by TipRanks, as submitted to the SEC.
Hedge Fund Confidence Signal
Hedge Fund Activity
Activity
Star Ranking
 Michael Rockefeller | Woodline Partners LP | Added | 2065.52% | $6,322,821 | 0.02% | ||
 Peter Kolchinsky | RA Capital Management | New | 100.00% | $43,516,377 | 0.45% | ||
| Aly St Pierre | GoalVest Advisory LLC | New | 100.00% | $59,163 | <0.01% | ||
| Andrew J.M. Spokes | Farallon Capital Management, L.L.C. | Not Changed | 0.00% | $1,183,260 | <0.01% |
FAQ
Which hedge funds hold Capricor Therapeutics?
The hedge funds that hold the most shares in Capricor Therapeutics are Peter Kolchinsky, Michael Rockefeller and Andrew J.M. Spokes.
Are hedge funds buying or selling DE:4LN2?
In the last quarter hedge funds have Decreased their holdings in Capricor Therapeutics by 149.4K shares.
Where can I see a list of the best rated hedge funds?
You can see a list of the best hedge funds here.
Who is the best-performing hedge fund manager?
The top-rated hedge fund managers can be seen here: Top Hedge Fund Managers
Does Warren Buffet hold shares in Capricor Therapeutics stock?
Warren Buffet currently does not own shares in Capricor Therapeutics.
What is a 13F filing, and how does it help investors?
A 13F form, also known as a "Report of Investment Manager," is a quarterly report that investment advisors registered with the Securities and Exchange Commission (SEC) must file if they manage at least $100 million in assets. The 13F form lists all of the publicly traded securities that the investment advisor owns as of the end of the reporting period. To read more about the 13F, click here
